



#### The STEP UP ALM comprises:

- **Module 1** self-directed activity
- **Module 2** face-to-face meeting
- **Module 3** self-directed activity

Please complete all components and submit to Lateral Connections, the education provider, within 30 days of the STEP UP meeting date to receive 40 Category 1 points.

The STEP UP face-to-face meeting (Module 2) is allocated a total of 3 Category 2 points, as part of the RACGP QI & CPD Program in the 2017-19 Triennium.

Activity number: 125859

The STEP UP ALM (Modules 1-3) is allocated 40 Category 1 points, as part of the RACGP QI & CPD Program in the 2017-19 Triennium.

Activity number: 125858



**References:** 1. Lung Foundation Australia - COPD-X Concise Guide for Primary Care. Available at [https://lungfoundation.com.au/wp-content/uploads/2014/11/LFA-COPD-X-doc\\_FINAL-190917.pdf](https://lungfoundation.com.au/wp-content/uploads/2014/11/LFA-COPD-X-doc_FINAL-190917.pdf) [Accessed March 2018]. 2. National Health Performance Authority 2015, Healthy Communities: Potentially preventable hospitalisations in 2013-14. 3. Suissa et al Thorax 2012 ;67:957-963. 4. Australian Bureau of Statistics. Causes of Death, Australia, 2016. Updated 7 Sep 2017. Available at <http://www.abs.gov.au> [Accessed December 2017]. 5. AIHW. COPD. Available at <https://www.aihw.gov.au/reports/asthma-other-chronic-respiratory-conditions/copd-chronic-obstructive-pulmonary-disease/contents/how-many-die-from-copd> [Accessed May 2018]. 6. Access Economics. Economic Impact of COPD and cost effective solutions 2008.

Lateral Connections is the education provider. This is an education event only for healthcare professionals. At Lateral Connections we comply with the National Privacy Principles. We may collect and store your personal information for the purposes of collating responses to the STEP UP program which may include disclosure to program sponsors, or third parties for the purpose of processing and collating the information. This information will be used and disclosed only in accordance with our Privacy Policy and not for any other purpose unless required to do so by law. By registering for STEP UP, you consent to the use of your information in this manner.

GlaxoSmithKline Australia complies with the Privacy Act 1988. Details of our privacy policy can be found at <http://au.gsk.com/en-au/privacy-policy/> If you require you may access the information we hold about you by writing to the Privacy Officer, GlaxoSmithKline, PO Box 18095, Melbourne, VIC 8003. GSK will disclose the cost of all hospitality provided for this meeting in a report that is published online, the names of attendees will not be included. Attendees are responsible for obtaining approval to receive and/or disclose hospitality as required by their employer or professional association. GlaxoSmithKline Pty Ltd. PO Box 18095, Melbourne VIC 8003. ABN 47 100 162 481.



This organisation is an authorised provider of accredited activities under the RACGP QI&CPD Program



Clinical content developed independently by Lateral Connections at the request of, and with funding from, GlaxoSmithKline Australia Pty Ltd. ACN 100 162 481. Level 4, 436 Johnston Street, Abbotsford, Victoria, 3067. AUS/TLY/0062/18 Date of Approval: June 2018



This educational program provides  
an update on strategies to reduce  
the risk of exacerbations in patients  
with moderate to severe COPD.

## INVITATION

Wed 18th Sept 2019



# THE BURDEN OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN AUSTRALIA

## 5th leading cause of death<sup>4,5</sup>

- 1 Heart Disease
- 2 Dementia
- 3 Cerebrovascular diseases  
ie. stroke
- 4 Throat and lung cancers
- 5 COPD<sup>5</sup>



In 2008  
COPD cost  
**\$8.8 billion<sup>6</sup>**

**Loss of productivity:**  
\$6.8 billion (76.6%)<sup>6</sup>

**Cost to health system:**  
\$900 million (9.7%)<sup>6</sup>



The frequency and severity  
of exacerbations is linked to  
**increased mortality risk<sup>1</sup>**

Emerging evidence points  
towards the merits of **stepping  
up therapy** with newer  
pharmacological approaches  
in patients with moderate/  
severe COPD with repeated  
exacerbations<sup>1</sup>



**2nd leading  
cause of avoidable  
hospital admissions<sup>2</sup>**

**10.4%** of all preventable  
hospitalisations with  
an average length  
of stay of  
**5.7 days**



## LEARNING OUTCOMES

- Examine the clinical evidence behind pharmacological strategies for reducing exacerbation risk in patients with moderate to severe COPD
- Determine appropriate pharmacological strategies to reduce the risk of exacerbations in patients with moderate to severe COPD
- Create a patient recall system to reassess the management of moderate to severe COPD patients who are at risk of exacerbations

Wednesday 18th Sept 2019

TIME/

6:30pm

VENUE/

Parklands Resort

ADDRESS/

121 Ulan Road,  
Mudgee, NSW,  
2850

SPEAKER/

Dr S Mallawathantri

Dr Suganya Mallawathantri is the Senior Staff Specialist and Head of Respiratory Service at Dubbo Hospital and is the Western NSW LHD Area Lead in Lung Cancer.  
Her main sub-speciality interests are lung cancer, pleural diseases, cystic fibrosis and bronchiectasis.

## AGENDA

- 6.30 pm Arrival and registration
- 6.55 pm Introduction
- 7.00 pm Presentation
- 8.30 pm Dinner
- 9.00 pm Meeting close

This meeting (Module 2) is a component of the STEP UP Active Learning Module (ALM); you will receive 3 Category 2 points for attendance alone.

In order to obtain the full 40 Category 1 credits allocated to this ALM, please complete the program modules before (Module 1) and after (Module 3) you attend this meeting.

## RSVP / REGISTRATION

Anne Surendra  
M2103

Please complete this registration form, print and fax to Melbourne Mailing on 03 9490 1555.

First name:  Surname:

Practice address:

Contact Number:  Email:\*

Please list any dietary requirements:

Representative name: Anne Surendra Contact Number: 0428 687 644

\*Email address is required if you wish to complete the full 40-point Category 1 ALM.